News

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending January 7, 2021.

While patients with rheumatoid arthritis on rituximab therapy have been reported to have insufficient serological responses to the COVID-19 vaccine, T cells, which protect against severe COVID-19, may be elevated after a third dose.

Results showed equivalent effectiveness in disease control between the novel drug, sirolimus, and the classic immunosuppressant, tacrolimus, for the treatment of systemic lupus erythematosus.

Patient-reported outcomes, in addition to physician assessment, suggest apremilast improves quality of life and symptoms of psoriatic arthritis within 6 months.

While patients with rheumatoid arthritis may benefit from either increasing or decreasing their dosage of tofacitinib, post-hoc analysis indicates that safety and efficacy of the medication is not impacted by these changes.

“As the therapeutic landscape for PsA evolves, evaluating the long-term safety of treatments is essential to understand benefit–risk profiles and inform patient care,” investigators explained.

An increased frequency of serious infections and antimicrobial prescriptions was seen in patients with rheumatoid arthritis currently being treated with a TNFi.

Treatment for rheumatoid arthritis has been associated with the development and worsening of some lung conditions. Test your knowledge with this quiz.

Review a hand-selected assortment of articles written for Rheumatology Network by top rheumatologists.

Catch up on Rheumatology Network's top highlights of the ACR 2021 Convergence.

A year in review of Rheumatology Network's top stories.

Check out our expert interviews with top rheumatologists this year.

Vitamin D has been shown to improve both disease activity and fatigue in patients with systemic lupus erythematosus.

Novartis receives approval for Cosentyx, their biologic treatment for enthesitis-related arthritis and juvenile psoriatic arthritis, in children and adolescents.

Patients with rheumatoid arthritis often have lung conditions. How much do you know about the risks of lung disease associated with rheumatoid arthritis? Test your knowledge with this quiz.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 17, 2021.

Cannabidiol (CBD) may be used separately or in conjunction with standard treatment to reduce symptoms of juvenile idiopathic arthritis.

“Although many different autoantibodies have been investigated in SLE, only a limited number of autoantibodies are being used in clinical practice,” investigators stated. “Due to these limitations, there has been great interest in the discovery of new autoantibodies that can be used in clinical practice.”

The US FDA approved upadacitinib (15 mg daily) for the treatment of adults with active psoriatic arthritis with inadequate response to at least 1 TNF blocker.

Test your knowledge of the treatment and management of rheumatoid arthritis with our latest RA quizzes.

"Understanding the effects of the pandemic on specific areas of health care is crucial for future planning in both the immediate and longer term," stated investigators.

Smoking increased the risk of developing malar rash and mucosal ulcers as well as increasing the likelihood of experiencing migraine, Raynaud’s phenomenon, and arthritis symptoms.

Women with systemic lupus erythematosus are more likely to have accelerated progression of atherosclerosis. Recognizing the risk factors, such as larger waist circumference and higher fasting glucose levels, may be an important step in preventing this condition.

“Preliminary evidence has suggested that an exercise training could be effective in improving physical function and quality of life in juvenile dermatomyositis, without exacerbating the disease,” investigators stated.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 10, 2021.

Investigators theorized that this questionnaire, in conjunction with autoantibody determination, could help screen for SLE in the early stages of the disease.

Jessica Walsh, MD, explains the importance of understanding treatment satisfaction and decision-making in patients with axial spondyloarthritis based on patient-reported outcomes.

Crohn’s disease inflames the gastrointestinal tract and causes consistent abdominal pain and diarrhea. Upadacitinib (AbbVie), a reversible Janus kinase (JAK) inhibitor, may be able to help patients achieve clinical remission.

Selective Janus kinase (JAK) inhibitor, upadacitinib, is now intended for adults with moderate-to-severe rheumatoid arthritis (RA) who have had inadequate response or intolerance to at least 1 tumor necrosis factor (TNF) blocker.

Rheumatoid arthritis often requires long-term treatment with disease-modifying antirheumatic drugs (DMARDs), but tapering and even cessation of DMARDs can be considered for patients in remission. Test your knowledge of use of DMARDs in patients in remission with this quiz.